More on DNLI

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.8 Score)

Upcoming Events

- Earnings (7/30/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Denali Therapeutics (NQ:DNLI)
Delayed: 26.48 +0.80 (3.12%)
Prev. Close $25.68  
Open$25.70 
52 Wk High$ 
52 Wk Low$ 
Day High$26.60 
Day Low$24.77 
P/E N/A  
EPS$ 
Volume1,894,519 

Friends, Peers and Foes (?): RPRX, ALNY, BIIB, WVE, ARCT (more...)

Jul 13, 2026 02:20 PM Denali Therapeutics (DNLI) call put ratio 1.3 calls to 1 put as share price up 2.2%
Jul 13, 2026 03:14 AM JPMorgan Resumes Denali Therapeutics Inc. (DNLI) at Overweight
Jul 9, 2026 04:01 PM Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Ba
Jul 8, 2026 11:30 AM Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: T. Rowe Price Investment Management, Inc.
Jun 22, 2026 09:26 AM
Jun 22, 2026 09:26 AM Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
Jun 18, 2026 08:02 AM Form 8-K Denali Therapeutics Inc. For: Jun 12
Jun 18, 2026 08:00 AM Denali Therapeutics to sell priority review voucher for $195M
Jun 18, 2026 08:00 AM Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
Jun 16, 2026 09:27 AM UBS Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
View All Articles

Entities mentioned with DNLI

View All Entities